Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

HY21 result: Volpara (ASX:VHT) reports more solid growth

Breast-imaging business Volpara Health Technologies Ltd (ASX: VHT) has released its FY21 half result with more solid growth.

HY21 report

Volpara revealed that its total revenue increased by 38% to NZ$9.5 million, with subscription revenue jumping 71% on the prior corresponding period to NZ$8.8 million.

In terms of its annual recurring revenue, which is if its existing subscriber base paid for a full year of subscriptions over the next 12 months, it increased to NZ$19.9 million (up 26.7% compared to last year’s number of NZ$15.7 million).

In terms of market share, Volpara said that approximately 27% of women had a group product applied on their images and data compared to around 25.8% at the end of the corresponding period, equating to an increase of 1.2 percentage points. Average revenue per user (ARPU) was US$1.16 million, which was up approximately 26%.

The Volpara gross profit jumped by 42.9% to NZ$8.68 million with the gross profit margin increasing to 92%, up from 89%.

Volpara reported a net loss after tax (before foreign currency effects) of NZ$8.9 million, which was 11% worse than the prior corresponding period.

The company said that continued investment has been made in research and development with the roll out of its Volpara Breast Health Platform, which is an end to end solution that’s fully integrated and delivered through a virtual appliance.

Volpara finished the half-year period to 30 September 2020 with NZ$64.3 million of cash.

Volpara’s outlook

The company says that its revenue is on track to match management’s expectations for the full year. It expects annual recurring revenue to keep rising, but coronavirus impacts are causing growth to slow particularly at hospital-based imaging centres.

Volpara expects ARPU to keep rising, but it may lose some clinics as it targets legacy MRS customers in support contracts (at very low ARPU) to upgrade to SaaS or risk not being supported. The SaaS contracts have much higher ARPU.

It also expects to see increasing revenue from its partnership with genetics company Ambry, which is starting to show significant ARPU potential, well above internal expectations.

With the ongoing strength of the business, and the increasing ARPU, gross profit margin and market share, I think Volpara looks like a very promising business that is worth being (at least) on your watchlist.

There are other ASX growth shares that have very attractive scalability in my opinion such as Pushpay Holdings Ltd (ASX: PPH).

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content